Fermer le menu


Member of Lyonbiopole


ReACT Therapeutics is a Grenoble-based biotech founded in January 2023 with the aim of restoring the efficacy of cancer treatments and improving the chances of remission for patients in therapeutic failure.

ReACT Therapeutics invented a potent and specific drug class to inhibit Breast Cancer Resistance Protein (BCRP), a transporter causing treatment resistance. Our lead drug, ValOMé, can impact existing and new cancer drugs by extending the duration of drug effect. We can impact across >40 known cancer drugs and >14 cancer indications. Our data shows ValOMé as safe, effective and selective.


Application market: Oncology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Small Molecules

Created on jan. 23rd, 2023 - 2 employees



93 Cours Berriat 38000 Grenoble



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.